Gothenburg, Sweden, 2015-10-30 13:41 CET (GLOBE NEWSWIRE) --
The Board of Immunicum has decided to explore the possibility of carrying out a listing of its shares on NASDAQ Stockholm’s main market in 2016. Immunicum’s shares are traded since April 22, 2013 on NASDAQ First North under the ticker IMMU.
The Board sees this as a natural next step for Immunicum to evaluate NASDAQ Stockholm as a new marketplace for the Company.
For further information, please contact:
Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com
The Company’s Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se
About Immunicum AB (publ)
Immunicum AB (publ) develops immunotherapies for the treatment of tumor diseases. A phase II study of the Company's most advanced cancer immune primer - INTUVAX® against renal cancer – has been initiated. The project portfolio contains an additional clinical phase I/II project in liver cancer.